Analysts See $-0.42 EPS for AMAG Pharmaceuticals, Inc. (AMAG)

October 2, 2018 - By Nellie Frank

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) LogoInvestors sentiment increased to 1.45 in Q2 2018. Its up 0.61, from 0.84 in 2018Q1. It improved, as 16 investors sold AMAG Pharmaceuticals, Inc. shares while 42 reduced holdings. 26 funds opened positions while 58 raised stakes. 43.35 million shares or 15.69% more from 37.48 million shares in 2018Q1 were reported.
Rocky Mountain Advisers Ltd Liability Company, Colorado-based fund reported 3,000 shares. Massachusetts Fincl Com Ma reported 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Fmr Limited Liability invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Renaissance Techs Ltd Liability owns 1.54 million shares. D E Shaw & Inc holds 0.03% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) or 1.01M shares. Pinebridge Invs L P owns 55,080 shares or 0.03% of their US portfolio. Ny State Common Retirement Fund invested in 0% or 44,000 shares. Blackrock holds 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 5.24 million shares. Wells Fargo Co Mn invested in 0% or 139,030 shares. Moreover, Citadel Advisors Ltd has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Piedmont Invest Advsr Ltd reported 7,999 shares or 0.01% of all its holdings. Parkside National Bank & Trust has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Stevens Cap Management Lp owns 13,980 shares. Exane Derivatives reported 2,356 shares stake. Armistice Capital Limited Liability Corp accumulated 2.08 million shares or 2.65% of the stock.

Since June 4, 2018, it had 0 insider purchases, and 1 sale for $500,000 activity.

Analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report $-0.42 EPS on November, 1.They anticipate $1.99 EPS change or 126.75 % from last quarter’s $1.57 EPS. After having $-0.75 EPS previously, AMAG Pharmaceuticals, Inc.’s analysts see -44.00 % EPS growth. The stock increased 0.91% or $0.18 during the last trading session, reaching $20.36. About 381,432 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 14.53% since October 2, 2017 and is uptrending. It has underperformed by 1.09% the S&P500.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 4 analysts covering Amag Pharmaceuticals (NASDAQ:AMAG), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Amag Pharmaceuticals had 9 analyst reports since May 3, 2018 according to SRatingsIntel. The rating was maintained by FBR Capital on Monday, August 6 with “Buy”. On Monday, May 21 the stock rating was initiated by Leerink Swann with “Hold”. The stock has “Hold” rating by Cantor Fitzgerald on Thursday, May 3. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Neutral” rating by Janney Capital on Friday, June 15. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Neutral” rating by Cantor Fitzgerald on Monday, August 6. The firm earned “Hold” rating on Sunday, June 17 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald with “Hold” on Monday, June 25. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Hold” rating given on Monday, June 4 by Cantor Fitzgerald. FBR Capital upgraded AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Friday, June 15 to “Buy” rating.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for women??s health, anemia management, and cancer supportive care in the United States. The company has market cap of $701.99 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

More recent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news were published by: Nasdaq.com which released: “AMAG Pharmaceuticals Pays Off $475 Million of Senior Secured Notes” on September 06, 2018. Also Nasdaq.com published the news titled: “AMAG Pharmaceuticals Partners With Emmy-Nominated Actress Cheryl Hines and Dr. Marla Shapiro to Start a …” on September 20, 2018. Nasdaq.com‘s news article titled: “AMAG Pharmaceuticals Acquires Orphan Drug Candidate for Treatment of Severe Preeclampsia” with publication date: September 26, 2018 was also an interesting one.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>